Strong start for Omisirge® launch with significant payer coverage and number of transplant centers onboarded exceeding expectations
Company continues to pursue strategic partnership to further. -Today at 07:02 am- MarketScreener
Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Gamida Cell Ltd. announced that the U.S. Food and Drug Administration has approved Gamida Cell s allogeneic cell therapy, Omisirge® , for use in adult and pediatric patients 12 years and. | April 18, 2023